EP Patent

EP1339713A2 — Saframycins, analogues and uses thereof

Assigned to Harvard University · Expires 2003-09-03 · 23y expired

What this patent protects

In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I), and methods for the synthesis thereof (I), In another aspect, the present invention provides phar…

USPTO Abstract

In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I), and methods for the synthesis thereof (I), In another aspect, the present invention provides pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. In yet another aspect, the present invention provides methods for treating cancer comprising administering a therapeutically effective amount of a compound of formula (I) to a subject in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP1339713A2
Jurisdiction
EP
Classification
—
Expires
2003-09-03
Drug substance claim
No
Drug product claim
No
Assignee
Harvard University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.